title: Abl silencing inhibits CAS-mediated process and constriction in resistance arteries.
abstract: The tyrosine phosphorylated protein Crk-associated substrate (CAS) has previously been shown to participate in the cellular processes regulating dynamic changes in the actin architecture and arterial constriction. In the present study, treatment of rat mesenteric arteries with phenylephrine (PE) led to the increase in CAS tyrosine phosphorylation and the association of CAS with the adapter protein CrkII. CAS phosphorylation was catalyzed by Abl in an in vitro study. To determine the role of Abl tyrosine kinase in arterial vessels, plasmids encoding Abl short hairpin RNA (shRNA) were transduced into mesenteric arteries by chemical loading plus liposomes. Abl silencing diminished increases in CAS phosphorylation on PE stimulation. Previous studies have shown that assembly of the multiprotein compound containing CrkII, neuronal Wiskott-Aldrich Syndrome Protein (N-WASP) and the Arp2/3 (Actin Related Protein) complex triggers actin polymerization in smooth muscle as well as in nonmuscle cells. In this study, Abl silencing attenuated the assembly of the multiprotein compound in resistance arteries on contractile stimulation. Furthermore, the increase in F/G-actin ratios (an index of actin assembly) and constriction on contractile stimulation were reduced in Abl-deficient arterial segments compared with control arteries. However, myosin regulatory light chain phosphorylation (MRLCP) elicited by contractile activation was not inhibited in Abl-deficient arteries. These results suggest that Abl may play a pivotal role in mediating CAS phosphorylation, the assembly of the multiprotein complex, actin assembly, and constriction in resistance arteries. Abl does not participate in the regulation of myosin activation in arterial vessels during contractile stimulation.
authors.affiliation: Center for Cardiovascular Sciences, Albany Medical College, Albany, NY 12208, USA.
authors.forename: Yana
authors.initials: Y
authors.lastname: Anfinogenova
authors.forename: Ruping
authors.initials: R
authors.lastname: Wang
authors.forename: Qing-fen
authors.initials: QF
authors.lastname: Li
authors.forename: Amy M
authors.initials: AM
authors.lastname: Spinelli
authors.forename: Dale D
authors.initials: DD
authors.lastname: Tang
mesh_terms: D000199:Actins / Q000378:metabolism; D000818:Animals; D050719:Crk-Associated Substrate Protein / Q000378:metabolism*; D020868:Gene Silencing; D008638:Mesenteric Arteries / Q000187:drug effects / Q000502:physiology*; D018994:Myosin Light Chains / Q000378:metabolism; D009924:Organ Culture Techniques; D010656:Phenylephrine / Q000494:pharmacology; D010766:Phosphorylation; D016315:Proto-Oncogene Proteins c-abl / Q000235:genetics* / Q000378:metabolism*; D050737:Proto-Oncogene Proteins c-crk / Q000378:metabolism; D051381:Rats; D014162:Transfection; D014443:Tyrosine / Q000378:metabolism; D014655:Vascular Resistance / Q000187:drug effects / Q000502:physiology; D014661:Vasoconstriction / Q000187:drug effects / Q000502:physiology*; D014662:Vasoconstrictor Agents / Q000494:pharmacology
chemical_list: D000199:Actins; C493843:Bcar1 protein, rat; D050719:Crk-Associated Substrate Protein; D018994:Myosin Light Chains; D050737:Proto-Oncogene Proteins c-crk; D014662:Vasoconstrictor Agents; D010656:Phenylephrine; D014443:Tyrosine; D016315:Proto-Oncogene Proteins c-abl